Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lakefront Biotherapeutics NV's enterprise value is $-1,552 Mil.
Lakefront Biotherapeutics NV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $469 Mil. Therefore, Lakefront Biotherapeutics NV's EV-to-EBITDA for today is -3.31.
The historical rank and industry rank for Lakefront Biotherapeutics NV's EV-to-EBITDA or its related term are showing as below:
LKFT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2830.22 Med: 2.37 Max: 759.82
Current: -3.47
During the past 13 years, the highest EV-to-EBITDA of Lakefront Biotherapeutics NV was 759.82. The lowest was -2830.22. And the median was 2.37.
LKFT's EV-to-EBITDA is ranked better than 99.75% of 398
companies
in the Biotechnology industry
Industry Median: 13.395
vs LKFT: -3.47
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lakefront Biotherapeutics NV's PE Ratio (TTM) for today is calculated as:
Lakefront Biotherapeutics NV's share price for today is $28.73.
Lakefront Biotherapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.705.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's EV-to-EBITDA falls into.
Lakefront Biotherapeutics NV's current Enterprise Value is $-1,552 Mil.
Lakefront Biotherapeutics NV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $469 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakefront Biotherapeutics NV (LKFT) has a EV-to-EBITDA of -3.31 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lakefront Biotherapeutics NV. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #1 out of 398 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Lakefront Biotherapeutics NV's EV-to-EBITDA too high?
Lakefront Biotherapeutics NV's current EV-to-EBITDA is -3.31. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #1 out of 398 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #1 out of 398 companies for EV-to-EBITDA. This places Lakefront Biotherapeutics NV in the top 0% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.40, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lakefront Biotherapeutics NV. For the Biotechnology industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakefront Biotherapeutics NV's current EV-to-EBITDA is -3.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (LKFT) is currently considered Possible Value Trap. The stock's GF Value™ is $130.36, compared to a current price of $28.73 — trading 78% below its estimated fair value. The current EV-to-EBITDA is -3.31. Lakefront Biotherapeutics NV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (LKFT), the current EV-to-EBITDA is -3.31 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (LKFT) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of $28.73 is trading 78% below its estimated GF Value™ of $130.36.
GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.
Key valuation signals for LKFT:
EV-to-EBITDA: -3.31
GF Value™: $130.36 vs. price of $28.73 (78% below fair value)
No single metric tells the full story. See the LKFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
66GF Score
Get the complete analysis for LKFT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LKFT has been successfully added to your 
